Join to View Full Profile
7979 Wurzbach RdSte 2222San Antonio, TX 78229
Phone+1 210-450-1143
Fax+1 210-450-0407
Dr. Shaheen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Damascus University Faculty of MedicineClass of 1996
Certifications & Licensure
NM State Medical License 2008 - 2027
TX State Medical License 2022 - 2025
AZ State Medical License 2016 - 2024
IN State Medical License 2000 - 2011
IL State Medical License 1997 - 2005
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Start of enrollment: 2018 Aug 29
Roles: Principal Investigator, Contact
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Roles: Contact
Publications & Presentations
PubMed
- Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, Farjana Fattah, Jason Y Park
JTO Clinical and Research Reports. 2025-01-01 - Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.Thomas J George, Ji-Hyun Lee, David L DeRemer, Peter J Hosein, Steven Staal
JCO Precision Oncology. 2024-12-01 - 120 citationsIndividualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas
Lancet. 2024-02-17
Journal Articles
- Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b StudyKaren Kelly, Montaser Shaheen, Shadia Jalal, Daruka Mahadevan, Clinical Cancer Research
Press Mentions
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 StudyNovember 2nd, 2021- Live from ASCO 2023 | for the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma That Failed Immuno-Oncologic (IO) TherapiesJune 6th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
